International Epilepsy Day

As every second Monday of February is commemorated the International Day of Epilepsy. The organizations that join this initiative year after year strive to improve the quality of life of people with epilepsy. More investment in research is requested from these organizations in order to develop new effective treatment to alleviate this disease and thus improve the quality of life of many people. "Epilepsy is a chronic brain disorder that promotes a convulsive response in the individual without distinction of sex or age. It is estimated that about 65 million people suffer from it in the world, placing it in the second neurological disease in the number of people affected, only behind headaches and near Parkinson and dementia. It should be noted that 80 per cent of people living in developing countries or low incomes, making it difficult for them to access treatments and social aids. As for the response to treatment, in about 30% of patients the response is null or does it inappropriately. It can start at any age but does it more often in the extreme ages of life, in childhood and in people over 65 years of age. As for the types, two large groups are differentiated, those of generalized crises (tonic-clinical, absences, myoclanics and atonics) and those of focal crises (with no alternation of consciousness, with alteration of consciousness and epileptic aura)." Source: https://medicinagaditana.es/insencias-13-de-febrero-de-2023-dia-international- Frequently asked questions: https://www.youtube.com/watch?v=W8bR2UXD8iQ In our unit we have several open trials for the inclusion of patients: Skyline: Multicentered, randomized, double-blind, placebo-controlled study and parallel groups to assess the effectiveness, safety and tolerability of soticlestat as adjuvant treatment in pediatric subjects and in young adults with Dravet syndrome (SD) Skyway: Multicentered, randomized, double-blind, placebo-controlled and parallel groups study to assess the effectiveness, safety and tolerability of soticlestat as adjuvant treatment in pediatric subjects and in adults with Lennox-Gastaut syndrome (SLG) Trust: Phase 3, double-blind, randomized, placebo-controlled trial of adjuvant therapy with gaxolone (GNX) in children and adults with epilepsy related to the tuberous sclerosis complex (TSC) Epy2001: Randomized, double-blind, placebo-controlled study of parallel and multicentered groups to assess the effectiveness, safety and tolerability of JNJ-40411813 as complementary treatment in subjects with epileptic crisis of focal start with sub-optimal response to miltiracetam. Legione: Phase 2, randomized, double-blind, placebo-controlled and multicentered study to assess the efficacy, safety and pharmacokinetics of rozanolixizumab in adults with autoimmune encephalitis associated with antibodies directed against protein 1 inactive of leucine-rich glioma If you are interested in participating, do not hesitate to contact us: /en/contacto.html